文献速递血栓与止血

腺病毒26型载体疫苗接种后抗血小板因子4抗体的评估

Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
PubMed 文献 · J Thromb Haemost · 2024-09-13

本研究评估腺病毒26型(Ad26)载体疫苗接种是否普遍诱导血小板因子4(PF4)抗体。在913名Ad26.COV2.S接种者和991名非COVID-19 Ad26载体疫苗临床试验参与者中,接种前后PF4抗体水平和阳性率相似;1例疫苗诱导免疫性血栓性血小板减少症(VITT)患者接种后出现血小板活化PF4抗体血清转化;28例血栓栓塞事件中仅1例、156名无血栓栓塞对照中2例在Ad26.COV2.S接种后血清转化;非COVID-19 Ad26疫苗接种后15例血栓栓塞病例无血清转化、77名对照中3例血清转化。结论认为Ad26载体疫苗通常不诱导PF4抗体或增加已有抗体水平,血栓栓塞事件与PF4抗体无关。

要点

  • Ad26载体疫苗接种前后PF4抗体水平和阳性率相似
  • VITT患者接种后出现血小板活化PF4抗体血清转化
  • Ad26接种后血栓栓塞事件与PF4抗体无关

核心结论

  • Ad26.COV2.S和其他研究的Ad26载体疫苗通常不诱导PF4抗体或增加已有PF4抗体水平。
  • 与VITT不同,Ad26疫苗接种后任何时间发生的血栓栓塞事件与PF4抗体无关。

研究设计与样本

  • 研究纳入Ad26.COV2.S临床试验中913名无血栓栓塞事件的健康参与者和非COVID-19 Ad26载体疫苗临床试验中991名无血栓栓塞事件的健康参与者,以及1名Ad26.COV2.S接种后发生VITT的参与者。
  • 在接种前和接种后血清中测量PF4抗体水平。
  • 在Ad26载体疫苗临床试验期间发生血栓栓塞事件的参与者中,以病例对照设置评估PF4抗体阳性率。

主要发现

  • 在1名VITT患者中,接种前PF4抗体阴性,接种Ad26.COV2.S后观察到血小板活化PF4抗体血清转化。
  • 在无血栓栓塞事件的参与者中,Ad26疫苗接种前后PF4抗体水平和阳性率相似。
  • Ad26疫苗接种未增加基线PF4抗体阳性参与者(n=47)的PF4抗体水平。
  • 在Ad26.COV2.S接种后,28例血栓栓塞病例中1例和156名无血栓栓塞对照中2例发生血清转化。
  • 在非COVID-19 Ad26疫苗接种后,15例血栓栓塞病例中无血清转化,77名无血栓栓塞对照中3例发生血清转化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse event identified following vaccination with some adenovirus-vectored COVID-19 vaccines, including Ad26.COV2.S. VITT is characterized by the presence of antibodies against platelet factor 4 (PF4). OBJECTIVES: To evaluate whether PF4 antibodies were generally induced following vaccination with adenovirus type 26 (Ad26)-vectored vaccines. METHODS: The study included 913 and 991 healthy participants without thromboembolic (TE) events in Ad26.COV2.S and non-COVID-19 Ad26-vectored vaccine clinical studies, respectively, and 1 participant with VITT following Ad26.COV2.S vaccination. PF4 antibody levels were measured in prevaccination and postvaccination sera. PF4 antibody positivity rates were assessed in a case-control setting in participants who developed TE events during participation in Ad26-vectored vaccine clinical studies. RESULTS: In the 1 VITT patient, PF4 antibodies were negative before vaccination. Seroconversion for platelet-activating PF4 antibodies was observed upon Ad26.COV2.S vaccination. In participants without TE events, the PF4 antibody levels and positivity rates were similar before and after Ad26 vaccination. Ad26 vaccination did not increase PF4 antibody levels in participants who were PF4 antibody-positive at baseline (n = 47). Lastly, 1 out of 28 TE cases and 2 out of 156 non-TE controls seroconverted after Ad26.COV2.S vaccination. None of the 15 TE cases and 3 of the 77 non-TE controls seroconverted following non-COVID-19 Ad26 vaccination. CONCLUSION: Ad26.COV2.S and the other Ad26-vectored vaccines studied did not generally induce PF4 antibodies or increase preexisting PF4 antibody levels. Moreover, unlike VITT, TE events that occurred at any time following Ad26 vaccination were not associated with PF4 antibodies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kristyanto H, Slaets L, Braams E, et al. Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines. J Thromb Haemost. 2024. PMID: 39278600. doi:10.1016/j.jtha.2024.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。